For retatrutide used within a clinical trial, adverse events should be reported through the trial sponsor's pharmacovigilance processes rather than via Yellow Card
regain likely reverses this benefit) Psychological cost of regain (depression, reduced self-efficacy, weight cycling) Potential need to restart treatment later (which may be less effective the second time) The break-even calculation: If continued treatment prevents regain that would otherwise require restarting treatment in 2 to 3 years, the cost of continuation is offset by avoiding the cost and difficulty of re-losing the weight
This difference is important because dietary supplements have specific labeling and manufacturing requirements, even though they are not FDA-approved before sale
The pause is therefore framed in research as protective and restorative , not as lost ground
A physician-supervised protocol does not end at the last injection
A study published in EMBO Reports shows that obesity can leave lasting changes at the cellular level through epigenetics, where gene activity is altered without changing the DNA itself